Egypt. J. Chem. **Vol.** 68, SI: Z. M. Nofal, pp. 1313- 1324(2025)

Egyptian Journal of Chemistry

http://ejchem.journals.ekb.eg/

Comprehensive Clinical Overview of Gallstones (Cholelithiasis): Epidemiology, Pathophysiology, Diagnosis, and Evidence-Based Management for Healthcare Professionals

Manar Obaid Alanazi*, Majed Battah Alshammari , Turki Saleh Alduhaim , Fahad Mohamed Alanazi, Jaber Ali Hassan Alshehri, Munirah Fayez Alharbi, Noran Mohammed Alghamdi, Nadyah Khalaf Safi Alanazi, Dalal Khalaf Safi Alanazi, Ghadeer Hemaidan Altalhi, Alanoud Salman Alshalawi

Ministry of National Guard, Saudi Arabia

Abstract

Background: Gallstones (cholelithiasis) are a prevalent digestive disorder affecting millions worldwide, with a higher incidence in women and older adults. While often asymptomatic, a significant minority develop symptoms or complications ranging from biliary colic to life-threatening conditions like cholecystitis, cholangitis, and pancreatitis.

Aim: This article provides a comprehensive clinical overview of gallstones for healthcare professionals, covering epidemiology, pathophysiology, diagnostic approaches, and evidence-based management strategies.

Methods: The review synthesizes current medical knowledge on gallstone formation, which involves an imbalance in bile composition (supersaturation of cholesterol or bilirubin), gallbladder stasis, and genetic, metabolic, and microbial factors. Diagnosis relies heavily on clinical history, physical examination, and ultrasonography as the primary imaging modality, with additional roles for CT, MRI/MRCP, and HIDA scans.

Results: Management is dictated by symptom presence and complication severity. Asymptomatic stones often require no intervention. For symptomatic or complicated disease, laparoscopic cholecystectomy is the definitive treatment. Endoscopic retrograde cholangiopancreatography (ERCP) is crucial for managing common bile duct stones, while conservative and medical therapies have limited, niche roles.

Conclusion: Gallstone disease represents a significant clinical and economic burden. Accurate diagnosis and risk stratification are essential. Surgical removal of the gallbladder remains the cornerstone of treatment for symptomatic patients, providing durable symptom resolution and preventing complications.

Keywords: Gallstones, Cholelithiasis, Epidemiology, Pathophysiology, Ultrasonography, Cholecystectomy, ERCP..

1. Introduction

Gallstones rank among the leading causes of digestive system dysfunction both nationally and internationally. They produce a spectrum of clinical effects that range from intermittent discomfort to persistent pain. They also trigger acute processes that affect the pancreas biliary tree liver and other segments of the gastrointestinal tract. In the United States gallstone disease affects millions. More than 6.3 million men and 14.2 million women between ages 20 and 74 have gallstones. Most affected people remain without symptoms yet a measurable minority progress to symptomatic disease. Approximately ten percent develop symptoms within five years of detection and about twenty percent do so within twenty years. Prevalence rises with age and exceeds twenty five percent among women older than sixty years. [1]

Stone formation reflects an interplay of metabolic influences environmental exposure and inherited predisposition. Stones vary in composition and in physical form. They may appear as fine particulate material or as discrete calculi that enlarge to several centimeters. Typically, mobile within the gallbladder lumen stones may become impacted either within the gallbladder body or at the cystic duct outlet. Fixation at these sites interferes with normal gallbladder contractile function reduces mucosal perfusion and fosters secondary infection. When stones impede bile flow and the gallbladder contracts against a partial obstruction, patients experience biliary colic. Biliary colic presents as episodic postprandial pain located in the epigastrium or the right upper quadrant and may reflect incomplete obstruction of the cystic or common bile duct. Early episodes are often self-limited and managed without hospital admission, but symptoms may persist or intensify leading to sustained inflammation and continuous pain. Prolonged or complete obstruction of the cystic duct precipitates acute cholecystitis while obstruction of the common bile duct predisposes to cholangitis and may trigger pancreatitis. Within hours of a sustained blockage the gallbladder wall becomes inflamed and bacteria from the gut may invade the biliary lumen. These processes can produce severe abdominal pain systemic inflammatory response and organ dysfunction. Chronic gallstone disease may lead to progressive scarring of the gallbladder wall and loss of contractile capacity resulting in biliary stasis and recurrent symptoms. [1]

*Corresponding author e-mail: alanazimo@gmail.com.;(Manar Obaid Alanazi).
Receive Date: 17 August 2025, Revise Date: 07 October 2025, Accept Date: 08 October 2025
DOI: 10.21608/ejchem.2025.413213.12170

Ultrasonography serves as the primary imaging modality for detecting gallstones. Stones are readily identified by ultrasound which provides high sensitivity for intraluminal calculi and permits assessment of gallbladder wall thickness and pericholecystic fluid that indicate inflammation. Computed tomography and magnetic resonance imaging also reveal stones in many cases and plain radiography can detect radiopaque calculi depending on their calcium content. Imaging complements clinical assessment and laboratory testing to define the acuity and complications of gallstone disease. Representative images demonstrate stone echogenicity on ultrasound and wall thickening with surrounding fluid on computed tomography consistent with acute cholecystitis. Treatment selection depends on clinical presentation severity and the presence of complications. For patients who experience recurrent biliary colic or who develop acute cholecystitis the accepted standard of care is laparoscopic removal of the gallbladder. This approach resolves symptoms and prevents further episodes by eliminating the reservoir that allows stone formation and impaction. In the United States surgeons perform approximately one million cholecystectomies each year with at least half of these procedures indicated for biliary colic or chronic cholecystitis. Surgical management follows thorough preoperative assessment and aims to minimize perioperative risk while restoring patient function. [2]

Conservative measures and nonsurgical options retain a role for selected patients. Medical therapy for gallstones includes agents that dissolve cholesterol rich stones but these treatments apply only to limited stone types and require prolonged courses with variable success. Endoscopic techniques address stones lodged in the common bile duct and provided a pathway to relieve obstruction and to reduce the risk of pancreatitis and cholangitis. Where immediate intervention is necessary for infection or sepsis image guided drainage and antibiotic therapy form part of the initial management. Overall gallstone disease encompasses a broad clinical spectrum. Many individuals remain asymptomatic yet a substantial subset progress to recurrent biliary colic acute inflammation and systemic complications. Accurate diagnosis relies on physical history examination and targeted imaging with ultrasound as the frontline test. Definitive therapy for symptomatic or complicated disease is surgical removal of the gallbladder through a laparoscopic approach which remains the predominant treatment in contemporary practice. [1][2]



Figure-1: Gallbladder Gallstones.

Etiology:

Bile acids originate in the liver through enzymatic conversion of cholesterol. Vitamin C facilitates this pathway by promoting hydroxylation steps that convert cholesterol into primary bile acids. Once secreted into the intestine, primary bile acids undergo bacterial and enzymatic transformations to yield secondary bile acids. Further modification by the intestinal microbiota or by hepatocytes produces tertiary bile acids. Structurally, bile acids possess a hydrophilic hydroxyl group, a conjugated glycine or taurine side chain, and a hydrophobic steroid nucleus, features that determine their solubility and detergent properties. [3] Gallstones form when soluble bile constituents precipitate and aggregate. The principal elements that nucleate and grow into calculi include cholesterol, pigments derived from hemoglobin breakdown, and a heterogeneous

mixture of calcium salts such as calcium bilirubinate, calcium phosphate, and calcium carbonate, along with cholesterol esters and fatty acids like palmitate. These solid components become entrapped within a mucinous glycoprotein matrix produced by the gallbladder epithelium. The matrix concentrates precipitated material and serves as a scaffold for crystal growth. Local mediators, including prostaglandins and lipid components such as arachidonyl lecithin, further facilitate crystallization and stone maturation. [4]

Cholesterol predominates in the most common stone phenotype. Cholesterol stones arise when bile becomes supersaturated with cholesterol relative to bile salts and phospholipids. Conditions that increase cholesterol secretion or reduce bile salt concentration favor supersaturation and nucleation. Metabolic disorders, notably diabetes mellitus and related dysmetabolic states, correlate strongly with cholesterol stone formation. In contrast, pigment stones vary by composition and pathogenesis. Black pigment stones consist chiefly of calcium bilirubinate and develop in contexts of increased bilirubin turnover. Hemolytic states and chronic inflammatory disorders of the biliary tract or bowel that accelerate hemoglobin catabolism predispose to black stone formation. Brown pigment stones typically form in an infected biliary system. Bacterial or parasitic colonization introduces enzymes that deconjugate bilirubin and alter the chemical milieu, promoting formation of stones that contain mixed calcium salts, cholesterol fragments, and bile components. These brown stones commonly arise within the biliary ducts in the setting of cholangitis or biliary stricturing. [4][5] The nucleation and growth process depends on multiple host and local factors. Gallbladder stasis promotes concentration of lithogenic components and prolongs contact time between mucin and bile, increasing the probability of crystal aggregation. Impaired gallbladder motility can be functional or secondary to chronic inflammation and fibrosis. Mucin hypersecretion and changes in mucin glycosylation enhance its capacity to entrap crystals. Genetic influences modulate bile acid synthesis, cholesterol transporters, and mucin production, explaining familial clustering and ethnic differences in stone prevalence. Dietary and environmental factors also alter lipid and bile composition and thus influence stone risk.

Anatomic and physiologic variants alter where stones originate and where they lodge. Primary gallbladder stones arise within the lumen of the gallbladder and may remain there indefinitely or migrate into the cystic duct or common bile duct. Migration and impaction explain the clinical presentations of biliary colic, acute cholecystitis, ascending cholangitis, and gallstone pancreatitis. Less commonly, primary calculi develop within the ductal system itself, particularly when stasis, infection, or obstruction present, creating a substrate for intraductal stone formation. [6] Overall, gallstone etiology reflects a multifactorial process. The balance among cholesterol solubility, bile salt concentration, mucin dynamics, gallbladder motility, genetic predisposition, metabolic co-morbidities, and biliary infection determines whether and what type of stones will form. Understanding these interacting mechanisms informs prevention strategies and guides clinical decisions regarding medical, endoscopic, or surgical management.



Figure 2: Common Bile Duct Stones.

Epidemiology

Gallstone disease affects a substantial segment of the adult population in the United States and worldwide. National estimates indicate that roughly 14 million women and 6 million men aged 20 to 74 harbor gallstones. Health care utilization related to symptomatic cholelithiasis remains high; in 2023 symptomatic gallstones generated approximately 2 million ambulatory visits and 1 million emergency department encounters. Surgical management continues at scale, with an estimated 605,000 outpatient and 280,000 inpatient laparoscopic cholecystectomies, in addition to 49,000 inpatient open cholecystectomies performed during that year. These figures reflect both the high prevalence of disease and its ongoing clinical and procedural burden. The frequency of gallstone disease rises with advancing age, and intervention rates have increased disproportionately among older adults, Hispanic populations, and women. Certain indigenous groups show particularly elevated prevalence estimates, with some reports citing rates as high as 70% in select cohorts. [7] The global pattern of gallstone composition displays notable geographic variation. Cholesterol-rich stones predominate in Westernized nations, and their incidence appears to be increasing. Estimates suggest that cholesterol gallstones may affect up to one fifth of the European population, a pattern that parallels the rising prevalence of metabolic disorders in those regions. In contrast, pigment stones derived from bilirubin remain more common in parts of the developing world. These pigment stones frequently correlate with underlying hemolytic conditions and with biliary infections that alter bilirubin metabolism and bile composition. The divergent etiologic profiles between high-income and low-income settings underscore the influence of environmental, infectious, and hematologic factors on stone pathogenesis. [8]

Longitudinal outcome data show that most individuals with asymptomatic gallstones do not develop symptomatic disease in the short term, but a measurable minority progress to clinical manifestations over time. Approximately 10% of persons with incidentally detected gallstones develop symptoms within five years of diagnosis, and about 20% become symptomatic within two decades, corresponding to an annual transition rate on the order of 1% to 2% per year. Among those who develop symptoms, a smaller fraction of experience complication; estimates place the complication rate at roughly 1% to 2% and identify common bile duct calculi as a frequent driver of adverse events. At the time of cholecystectomy, common duct stones are identified in 5% to 15% of patients, with the likelihood of ductal calculi increasing with patient age. Registry data from Sweden reported a detection rate of choledocholithiasis in approximately 11% of intraoperative cholangiograms performed for symptomatic gallstone disease. [9][2][10] Multiple host and lifestyle factors associate with heightened gallstone risk, particularly for cholesterol stones. In Western populations roughly three quarters of gallstones are cholesterol based. These stones cluster with metabolic disturbances including dyslipidemia, diabetes mellitus, obesity, and insulin resistance. Dietary patterns characterized by higher saturated fat and sugar intake and lower fiber consumption further promote lithogenic bile. Physical inactivity and physiologic states that reduce gallbladder contractility also contribute; rapid weight loss, prolonged fasting, and other conditions that blunt gallbladder emptying facilitate supersaturation of bile with cholesterol and favor nucleation. Genetic predisposition accounts for a substantial proportion of interindividual risk, with heritability estimates in the range of 25% to 30%, reflecting polymorphisms that affect hepatic cholesterol handling, bile acid synthesis, and biliary transport mechanisms. [3][11][12][5]

Sex hormones exert a measurable effect on biliary physiology. Estrogen increases bile cholesterol content and diminishes gallbladder contractile response, mechanistic effects that translate into higher incidence among women. Women of reproductive age and users of estrogen-containing contraceptives exhibit roughly twice the risk of gallstone formation compared with men, a difference that narrows after menopause but contributes to the overall sex disparity in prevalence. Clinical implications of hormonal influence extend to pregnancy, hormone replacement therapy, and exogenous estrogen exposure in other settings. [13] Taken together, the epidemiology of gallstones reflects interactions among demographic trends, metabolic health, genetic predisposition, hormonal milieu, and infectious or hematologic pressures in specific populations. The disease imposes a sustained clinical load through ambulatory and acute care encounters and drives a large volume of elective and urgent surgical procedures. Shifts in population age structures, obesity prevalence, and metabolic disease incidence will continue to shape the future burden of gallstone disease and the demand for diagnostic and therapeutic services.

Pathophysiology

Gallstone formation begins when the chemical equilibrium of bile is disturbed, and solutes exceed their capacity to remain dissolved. Supersaturation of bile with cholesterol or pigment components permits nucleation of microscopic crystals. These crystals become entrapped in the gallbladder mucin layer, leading to the formation of sludge. Continued aggregation and accretion of crystalline material within the mucin scaffold produce macroscopic calculi that may enlarge over time and ultimately occupy substantial volume within the gallbladder lumen. Stones formed in this manner typically remain mobile but can migrate into the cystic or common bile ducts, where their presence may produce obstructive complications including ascending cholangitis and pancreatitis when biliary flow is interrupted. By contrast, pigment stones composed predominantly of calcium bilirubinate may develop primarily within the ductal system rather than the gallbladder lumen. [13][10] Multiple physiologic and pathologic states predispose to stone formation by promoting lithogenic bile, bile stasis, or both. Cirrhosis, procedures that impair autonomic control of the biliary tract such as spinal cord injury, and surgical alterations including gastrectomy increase the risk of stones by slowing gallbladder emptying or changing bile composition. Certain drugs, notably somatostatin analogs and estrogenic agents, alter bile secretion or gallbladder motility and thereby favor stone formation. Structural and functional changes in gallbladder innervation have been documented in patients with cholelithiasis, indicating that diminished neural input may contribute to impaired contractility and promote conditions favorable to nucleation and growth of stones. [11]

Cholesterol stones arise when hepatic secretion of cholesterol and the presence of triglyceride-rich bile exceed the solubilizing capacity of bile acids and phospholipids. This imbalance induces mucin hypersecretion by the gallbladder mucosa, increases fasting gallbladder volume, and reduces postprandial emptying. Impaired intestinal transit and slowed motility further magnify the lithogenic state by altering enterohepatic cycling of bile acids. Excess biliary cholesterol also

provokes mucosal changes in the gallbladder wall, including hyperplasia and inflammation, which may perpetuate stasis and provide a microenvironment for crystal retention and growth. The pathogenesis of cholesterol gallstones therefore integrates metabolic, hormonal, microbial, and mechanical influences. [3][11][14] Dietary patterns and metabolic abnormalities modulate these processes. High intake of fructose accelerates hepatic gluconeogenesis and lipogenesis. Accumulated glycogen intermediates divert substrates into triglyceride synthesis, and resultant hypertriglyceridemia impairs gallbladder emptying through reduced responsiveness to cholecystokinin. Insulin resistance exacerbates this milieu by upregulating hepatic cholesterol synthesis via HMG-CoA reductase, increasing cholesterol secretion into bile, and reducing intestinal cholesterol absorption in a manner that further enhances hepatic cholesterol production. Obesity amplifies these effects by enlarging hepatocytes and altering perfusion, which contributes to metabolic signaling changes that favor lithogenesis. Consequently, gallstones both reflect and reinforce systemic metabolic dysfunction, establishing bidirectional relationships with disorders such as diabetes and dyslipidemia. [3][11][14]

Molecular and transporter biology also govern biliary cholesterol load. Variations in cholesterol transporters affect the relative distribution of cholesterol between blood and bile. Lecithin and phospholipid lamellae play critical roles in solubilizing excess cholesterol; alterations in phospholipid homeostasis change the physical state of bile and influence formation of cholesterol hydrate crystals. These crystals provide nuclei for stone growth. In addition, local lipid mediators such as prostaglandins and arachidonyl lecithin modify membrane dynamics and facilitate crystallization. When gallbladder contractility is reduced, the residence time of bile increases and the window for crystallization expands. Phospholipid-cholesterol interactions, mucin secretion, and inflammatory signaling converge to promote particle aggregation. [14] Immune and inflammatory responses materially influence stone development. Cholesterol crystals attract granulocytes and neutrophils, and neutrophils can release nuclear material, including DNA, onto the crystal surface. This extracellular DNA and associated neutrophil extracellular trap components create an adhesive substrate that promotes further crystal aggregation. The result is an incremental enlargement of stones driven by host inflammatory processes as well as physicochemical precipitation. Mucin glycoprotein changes that increase stickiness and entrapment of crystals amplify nucleation efficiency. These host responses explain why chronic inflammation of the gallbladder and repeated cycles of stasis accelerate stone growth and persistence. [5][11][14]

Genetic determinants and pharmacologic modifiers alter individual susceptibility. Polymorphisms in genes regulating hepatic cholesterol secretion, apolipoprotein composition, mucin production, and fibroblast growth factor signaling have been associated with increased gallstone risk. Specific allelic variants, such as a mucin-like protocadherin polymorphism (rs3758650), correlate with higher incidence of symptomatic stones. Gene-environment interactions and epigenetic modifications in response to metabolic stressors like insulin resistance can upregulate biliary cholesterol secretion. Conversely, experimental gene deletions that reduce biliary cholesterol export or increase hydrophilic bile acid synthesis mitigate stone formation, illustrating the causal role of transporter and synthetic pathways. Pharmacologic agents that interfere with intestinal cholesterol absorption, for example ezetimibe, shift homeostatic feedback loops and may paradoxically stimulate hepatic cholesterol synthesis if compensatory mechanisms are activated, thereby modifying stone risk. [11][14] The gut microbiome exerts a significant influence over bile composition and gallstone risk. Bacterial taxa differ between individuals with and without gallstones, and organisms capable of producing biofilms are implicated in nucleation and stone consolidation. Gram-positive anaerobes have been linked to higher concentrations of the secondary bile acid deoxycholate, a metabolite that promotes cholesterol supersaturation and crystallization. Genomic analyses of bacterial communities within cholesterol versus pigment stones reveal distinct microbial signatures, with gram-positive species more commonly identified in cholesterol-containing calculi. Microbiota modulate cholecystokinin release and regulate mucin gene expression, thereby affecting gallbladder motility and mucin-mediated nucleation. Experimental work demonstrates that bacterial slime production and other microbial properties accelerate stone nucleation in bile-like media, supporting a mechanistic role for microbes in lithogenesis. Changes in microbial diversity, loss of beneficial commensals, and overgrowth of pathogenic bacteria contribute to the lithogenic state and to mixed stone formation when microbial colonization coincides with elevated bilirubin or inflammatory infiltration. [16][17][14][18]

Environmental toxins and external exposures also intersect metabolic and microbial drivers. Persistent organic compounds such as polyfluoroalkyl substances (PFAS) accumulate in plasma, liver, kidneys, and bile, perturbing enterohepatic circulation and interfering with lipid metabolism, hepatocellular function, and hormonal regulation. Such disruptions can alter bile acid composition and cholesterol handling in ways that facilitate stone formation. High altitude has been linked to increased gallstone risk through hypoxia-induced shifts in hepatic metabolism, including upregulation of hypoxia-inducible factor 1 alpha and increased activity of monooxygenases such as trimethylamine-N-oxide (TMAO) pathways, biochemical changes that may favor cholesterol supersaturation in bile. Exposure to pesticides, heavy metals, and other xenobiotics further modifies gut microbiota and hepatic function, thereby influencing stone risk. [19][20][11] Microbial, genetic, metabolic, hormonal, and environmental factors converge to create a spectrum of phenotypes ranging from pure cholesterol stones to pigment and mixed stones. Clinical correlates reflect these mechanisms: cholesterol stones predominate in populations with metabolic syndrome, obesity, and Western dietary patterns, whereas pigment stones are associated with hemolysis, biliary infection, and conditions that increase bilirubin load. Reduced gallbladder emptying, whether from autonomic denervation, hormonal modulation such as estrogen-mediated decreases in bile acid synthesis, or changes in neurohormonal regulators like vasoactive intestinal peptide and fibroblast growth factor, extends bile residence time and promotes crystal growth. Estrogen specifically increases hepatic cholesterol secretion and shifts bile composition toward lithogenicity by acting through estrogen receptor-mediated pathways. [11][14]

Finally, the pathophysiology of gallstones is self-reinforcing. Stones alter gallbladder function by promoting local inflammation, fibrosis, and further impairment of contractility. Recurrent stasis and repeated episodes of mucosal injury perpetuate a cycle of worsening lithogenesis and symptomatic disease. The interplay among gallbladder mechanics, bile chemistry, microbial ecology, host inflammation, and genetic predisposition determines whether microscopic crystallization proceeds to clinically relevant stone disease. Understanding these interacting pathways informs preventive strategies, guides

selection of medical or surgical interventions, and frames research into targeted therapies that modify bile composition, improve gallbladder motility, or reshape microbiome-host interactions to reduce the burden of cholelithiasis.

History and Physical

Gallstones are often silent and found incidentally on imaging. Many individuals remain asymptomatic for years. Others develop episodic biliary colic. Typical colic is crampy, postprandial pain in the right upper quadrant or epigastrium. The pain commonly radiates to the back or right scapula. High-fat meals frequently precipitate attacks. Nausea and vomiting commonly accompany the pain. Early episodes tend to resolve without hospital care. Laboratory tests and vital signs may be normal between attacks. [10][21] When a stone causes sustained obstruction, the clinical picture changes. Acute cholecystitis develops when the gallbladder wall becomes inflamed, often after prolonged cystic duct obstruction. The pain becomes constant and progressive. Patients report severe right subcostal pain that worsens with deep inspiration. Palpation elicits marked tenderness beneath the costal margin and may produce a positive Murphy sign. Fever and tachycardia are common. On examination a tender, palpable mass may represent an edematous gallbladder. Laboratory studies often show leukocytosis and elevated inflammatory markers. Imaging usually confirms gallbladder wall thickening and pericholecystic fluid. [10][21]

Obstruction of the common bile duct produces cholestatic features. Jaundice and dark urine are frequent findings. Scleral icterus and pruritus may be present. Biochemical testing typically shows raised bilirubin and cholestatic liver enzymes. Stones lodged near the pancreatic duct increase the risk of gallstone pancreatitis. Presentation in that case includes severe mid-epigastric pain radiating to the back, persistent vomiting, and systemic inflammatory signs. Serum amylase and lipase are elevated. Physical exam may reveal epigastric tenderness with guarding and diminished bowel sounds. [21] Ascending cholangitis represents a serious infectious complication of biliary obstruction. The classic triad consists of fever, right upper quadrant pain, and jaundice. Hemodynamic instability altered mental status, and shock signal progression to Reynold pentad and require immediate intervention. Patients may present with hypotension, tachycardia, and impaired mental status. Rapid recognition and early biliary decompression are essential to reduce mortality. Blood cultures and biliary cultures guide targeted antimicrobial therapy. [21]

The physical examination may be subtle when stones are not impacted. Between episodes many patients show only mild RUQ or epigastric tenderness. Vital signs may be stable and laboratory tests are near normal. This clinical silence emphasizes the need to integrate history with focused imaging. Ultrasonography is the preferred first test for detecting gallstones and for evaluating complications. When findings are equivocal, cross-sectional imaging or endoscopic evaluation may be necessary. Risk stratification relies on the pattern of symptoms and objective findings. Isolated, brief postprandial pain without systemic signs suggests uncomplicated biliary colic and can be managed conservatively or electively. Constant severe pain, fever, leukocytosis, or abnormal liver tests raise concern for cholecystitis, choledocholithiasis, cholangitis, or pancreatitis and indicate urgent evaluation. Physical signs such as Murphy's sign, palpable RUQ mass, jaundice, or hemodynamic instability increase the pretest probability of complications and should prompt expedited imaging and surgical consultation. Timely differentiation among these entities determines the need for admission, antibiotic therapy, biliary decompression, or urgent cholecystectomy. [10][21]

Evaluation

Right upper quadrant ultrasonography serves as the primary imaging test when gallstones are suspected. It detects calculi as small as 2 mm and identifies sludge and polyps within the gallbladder. The modality demonstrates high specificity, reported at approximately 90 percent for gallstones. Ultrasonography also evaluates secondary signs that suggest complication, including gallbladder wall thickening, pericholecystic fluid, and a sonographic Murphy sign, each of which supports a diagnosis of acute cholecystitis. Despite its strengths, ultrasonography is imperfect for every clinical scenario. It frequently identifies stones incidentally on studies obtained for other reasons. Computed tomography and magnetic resonance imaging also reveal gallstones on occasion but lack the sensitivity of ultrasound for direct stone detection and are less reliable than ultrasound for the initial assessment of acute cholecystitis. Plain radiography visualizes roughly ten percent of gallstones because only a minority are radiopaque. A HIDA or hepatobiliary iminodiacetic acid scan uses a radiotracer to map hepatobiliary excretion and concentrate in the gallbladder. When tracer fails to enter the gallbladder, the finding indicates cystic duct obstruction and supports the diagnosis of acute cholecystitis. The HIDA scan also measures gallbladder function and can demonstrate a persistently low ejection fraction consistent with biliary dyskinesia. These functional data complement structural imaging when the clinical picture is equivocal. [22]

Imaging of the biliary tree targets common duct stones when obstruction is suspected. Dilatation of the common bile duct on ultrasound, CT, or MRI signals the possibility of retained or recently passed choledocholithiasis. MRCP provides noninvasive cross-sectional mapping of the biliary and pancreatic ducts and displays high sensitivity and specificity for ductal calculi. ERCP matches MRCP for diagnostic accuracy and adds the advantage of therapeutic access, permitting stone extraction, sphincterotomy, and stent placement in the same session. ERCP therefore carries both diagnostic and therapeutic value but requires specialist availability and carries procedural risks that must be weighed against potential benefit. When ERCP is not available or is contraindicated, alternative approaches include percutaneous transhepatic cholangiography or intraoperative cholangiography performed during laparoscopic cholecystectomy. Surgeons vary in their practice; some perform routine intraoperative cholangiograms while others reserve the technique for selective cases based on preoperative imaging or intraoperative findings. Fluoroscopic intraoperative cholangiography can identify ductal stones in real time and guide intraoperative management. [10]

Clinical pathways that stratify patients by severity and by the likelihood of complication structure the diagnostic workup. Professional societies and national guidelines outline criteria that separate patients with uncomplicated gallstones from those with acute or complicated cholecystitis. The Japanese Society of Gastroenterology, in its 2021 revision, recommends classifying patients after imaging into groups with or without cholecystitis using objective measures such as focal right upper quadrant pain, elevated white blood cell count, elevated C-reactive protein, pericholecystic fluid, and

gallbladder wall thickening. These criteria guide whether immediate intervention, hospital admission, or outpatient management is appropriate. [9] Laboratory testing refines the clinical assessment and screens for biliary obstruction, infection, and organ dysfunction. A complete blood count can reveal leukocytosis that supports an inflammatory or infectious process. Liver function tests serve to detect cholestasis and hepatocellular injury. Alkaline phosphatase and gamma-glutamyl transferase typically rise with biliary obstruction. Aminotransferases may show mild to moderate elevation in the early phases of obstruction or inflammation. Conjugated hyperbilirubinemia indicates impaired bile flow and commonly accompanies common duct obstruction. In contrast, patients with asymptomatic gallstones or with stones that transit the ductal system without impaction often have normal laboratory studies. Measurement of inflammatory markers such as C-reactive protein helps stratify severity when infection or systemic inflammation is suspected. [23]

The diagnostic algorithm integrates history, physical findings, laboratory results, and imaging to reach a working diagnosis and plan treatment. In a patient with typical postprandial right upper quadrant pain, a negative ultrasound may prompt a HIDA scan when functional biliary dyskinesia or acalculous cholecystitis is considered. Conversely, in a patient with RUQ pain, fever, leukocytosis, and sonographic signs of inflammation, urgent surgical consultation is warranted. Evidence of common duct dilation or abnormal liver tests triggers consideration of MRCP or ERCP depending on resource availability and clinical urgency. When imaging and labs suggest complicated disease such as gangrene, perforation, or emphysematous cholecystitis, cross-sectional imaging with CT offers greater sensitivity to gas, necrosis, and peritoneal involvement and informs the need for drainage or expedited operative care [23]. Timing of interventions follows risk stratification. Patients with uncomplicated biliary colic may undergo elective laparoscopic cholecystectomy. Patients with acute cholecystitis commonly benefit from early cholecystectomy within the index admission when feasible. Those with choledocholithiasis and cholangitis may require urgent ERCP for biliary decompression followed by cholecystectomy once the infection is controlled. In critically ill patients or when surgery poses prohibitive risk, percutaneous cholecystostomy guided by ultrasound or CT provides temporary decompression and source control. In sum, evaluation of suspected gallstone disease centers on ultrasound as the initial test, supplemented by functional imaging such as HIDA when results remain uncertain, and by MRCP or ERCP when common duct stones threaten biliary flow. Laboratory studies provide biochemical context and help identify complications. Imaging choice and procedural sequencing depend on clinical presentation, local resources, and the need for simultaneous diagnosis and therapy. Integration of these elements yields a targeted, efficient diagnostic pathway that minimizes delay to definitive management while reducing unnecessary procedures [23].

Treatment / Management

Management of cholelithiasis spans conservative measures, interventional procedures, endoscopic therapies, and surgical approaches, with the treatment choice dictated by symptom burden, complication status, patient comorbidity, and operative risk. For patients with uncomplicated biliary colic, initial care often emphasizes conservative measures. Dietary modification that reduces fat intake lowers the frequency and severity of postprandial episodes. Symptom control relies on antiemetics and analgesics, and clinicians provide counseling about the natural history of gallstone disease and the risk of recurrence. Patients who experience recurrent colic despite conservative management are candidates for elective laparoscopic cholecystectomy, which remains the definitive therapy to prevent further symptomatic episodes and to eliminate the reservoir that permits stone formation.

Hospital admission and expedited intervention become necessary when symptoms escalate in severity or when the patient cannot tolerate oral intake. Stones that become impacted and produce persistent, unremitting pain require timely surgical management because prolonged obstruction increases the likelihood of inflammation, infection, and other complications. Stones larger than 1 cm have a greater propensity to obstruct the cystic duct and therefore warrant a lower threshold for operative treatment. Laparoscopic cholecystectomy is the preferred surgical modality for symptomatic stones because it provides effective, durable symptom relief with reduced perioperative morbidity compared with open approaches. Open cholecystectomy remains appropriate when dense adhesions, distorted anatomy, uncontrolled bleeding, or patient factors make laparoscopic dissection unsafe; conversion rates depend on intraoperative findings and surgeon experience. For acutely ill or physiologically fragile patients who cannot tolerate general anesthesia or definitive surgery, percutaneous cholecystostomy placed by interventional radiology offers a temporizing or palliative option that provides source control and symptomatic relief until the patient stabilizes or until definitive management can be considered. [10]

When choledocholithiasis is present, restoration of ductal patency is a priority because obstructed bile flow carries risks of cholangitis and biliary pancreatitis. Endoscopic retrograde cholangiopancreatography (ERCP) permits diagnosis and therapeutic stone extraction and can be performed preoperatively, intraoperatively, or postoperatively depending on local practice patterns and resource availability. Intraoperative strategies include laparoscopic or open common bile duct exploration. These techniques access the duct through the cystic duct or via choledochotomy and employ fluoroscopy or direct visualization with a choledochoscope. Choledochoscopic inspection allows direct stone removal but requires additional equipment and technical expertise. Choledochotomy introduces a risk of postoperative ductal stenosis when closed primarily, a complication surgeons may mitigate by constructing biliary-enteric anastomoses such as a Roux-en-Y choledochojejunostomy in select cases. Use of a T-tube for external drainage is an alternative that allows postoperative cholangiography and controlled decompression; however, the T-tube may act as a conduit for ascending infection, and displacement risks can precipitate bile leak and peritonitis. [24]

A hybrid intraoperative ERCP technique provides another option for managing ductal stones. In this coordinated approach a guidewire is introduced through the cystic duct and advanced across the Ampulla of Vater into the duodenum, where endoscopic retrieval enables subsequent sphincterotomy and stone extraction. This method reduces the need for a separate postoperative endoscopic procedure, shortens hospital stay, decreases total anesthesia exposure, and lowers overall cost when compared with staged interventions. It demands close collaboration between surgical and endoscopic teams and access to experienced endoscopists, which may limit its availability to centers with integrated services. [10]

Ascending cholangitis represents a biliary emergency that requires prompt decompression of the obstructed duct and early antimicrobial therapy. Biliary drainage may be achieved endoscopically via ERCP, percutaneously through transhepatic routes, or surgically if endoscopic and percutaneous access are not feasible. Early and adequate drainage reduces systemic inflammatory response and prevents progression to sepsis and multiorgan failure. Gallstone pancreatitis similarly requires rapid assessment and supportive care; cholecystectomy is typically deferred until the acute inflammatory process resolves, with interval cholecystectomy performed once the patient recovers to prevent recurrent episodes. [8][25] Nonoperative stone removal techniques have limited roles in modern practice owing to variable efficacy, logistical challenges, and recurrence risk. Extracorporeal shock-wave lithotripsy, mechanical lithotripsy, electrohydraulic lithotripsy, and laser lithotripsy may fragment difficult common duct stones when standard endoscopic extraction fails. Mechanical lithotripsy serves as a rescue after failed sphincterotomy, whereas electrohydraulic and laser modalities permit fragmentation under direct visualization or fluoroscopic guidance. These adjunctive techniques can increase stone clearance in selected cases but require specialized equipment, training, and often prolonged procedural time. Extracorporeal shock-wave lithotripsy may be uncomfortable and carries risks including hemobilia, arrhythmia, cholangitis, pancreatitis, and ileus; it is contraindicated in the presence of portal vein thrombosis or prominent abdominal varices and does not prevent de novo stone formation. In general, lithotripsy is reserved for complex cases and as a component of multimodal management rather than as primary therapy. [8][10]

Medical therapies to dissolve stones or reduce formation have niche applications. Ursodeoxycholic acid promotes gradual dissolution of small, cholesterol-rich stones and can be used in patients who decline or cannot undergo surgery. Dissolution rates are modest, often less than 50 percent, require months to years of therapy, and the underlying lithogenic milieu remains uncorrected, leading to substantial recurrence after cessation. Statins and agents that modify cholesterol absorption or synthesis, such as ezetimibe, affect hepatic cholesterol handling and have been explored as preventive measures; their net impact on gallstone incidence is biologically plausible but clinically modest and not a substitute for definitive therapy when symptoms or complications occur. Alternative and complementary remedies, including certain botanical extracts and nutraceuticals, have been reported in the literature but lack robust randomized evidence and are not widely endorsed as first-line treatments. [2][5] Perioperative and supportive management is integral to safe care. Analgesia, intravenous fluids, and antibiotics are employed as indicated for acute cholecystitis, cholangitis, or sepsis. Early cholecystectomy during the index admission is associated with shorter overall hospital stay and fewer readmissions for many patients with acute cholecystitis, provided surgical risk is acceptable. For high-risk surgical candidates, percutaneous drainage and interval cholecystectomy or long-term conservative management may be appropriate. Prophylactic measures aimed at modifiable risk factors—weight management, glycemic control, and judicious use of hormone therapy—contribute to primary prevention but have limited immediate impact on an existing symptomatic stone. Decision making should balance the risks and benefits of intervention, prioritize source control in infected or obstructed biliary systems, and adopt the least invasive effective approach. Coordination among surgeons, gastroenterologists, interventional radiologists, and anesthesiologists optimizes timing and modality of therapy. When definitive cholecystectomy is planned, laparoscopic technique remains the standard for most patients; when anatomy or physiology precludes safe laparoscopy, conversion to open cholecystectomy or staged management with percutaneous decompression provides a clear pathway to mitigate risk and relieve symptoms. Overall, management strategies for gallstone disease emphasize prompt recognition of complications, tailored procedural choice for ductal clearance, and definitive removal of the gallbladder when recurrent symptoms or complications threaten patient health and quality of life [24].

Differential Diagnosis

The clinical manifestations of gallstone disease can overlap with a variety of abdominal, thoracic, and vascular conditions, making accurate diagnosis essential to avoid inappropriate management. Biliary colic and acute cholecystitis typically present with right upper quadrant or epigastric pain, nausea, and vomiting, yet similar symptoms are frequently observed in several other disorders that must be considered in the diagnostic process. Appendicitis represents a key mimic, particularly when pain localizes in the right upper quadrant due to a high-lying appendix. Both conditions present with abdominal pain, nausea, and fever, but careful localization, physical examination, and imaging are critical for differentiation. Similarly, renal calculi can produce acute flank or abdominal pain radiating to the groin, and hematuria is a distinguishing feature. Imaging such as non-contrast CT of the abdomen is often required to confirm renal stones and exclude gallbladder pathology [25]. Malignant disease of the biliary tree, especially cholangiocarcinoma, may also resemble symptomatic cholelithiasis. Patients may present with jaundice, abdominal pain, and abnormal liver function tests, but the progressive nature of symptoms, weight loss, and imaging findings raise suspicion for malignancy. Pancreatitis due to causes other than gallstones must also be distinguished, as both present with epigastric pain radiating to the back, nausea, and vomiting. Elevated serum amylase or lipase levels, combined with cross-sectional imaging, assist in establishing the diagnosis. Peptic ulcer disease and gastroesophageal reflux disease are additional considerations. Both can cause epigastric pain and dyspepsia that may be confused with biliary colic. Endoscopy and response to acid-suppressive therapy often clarify the diagnosis. Likewise, esophageal spasm can present with chest or epigastric pain, occasionally severe and mimicking gallbladder disease, but diagnostic studies such as manometry and esophagram help identify motility disorders [25].

Cardiovascular conditions may also be misdiagnosed as gallbladder pathology. Myocardial infarction can present epigastric discomfort, nausea, and diaphoresis, especially in elderly or diabetic patients. Electrocardiography and cardiac enzyme evaluation are essential in excluding cardiac causes before proceeding with abdominal surgery. Aortic dissection may also present with acute abdominal or back pain, requiring urgent recognition through imaging such as CT angiography. Pulmonary conditions like pneumonia, particularly involving the right lower lobe, may produce referred abdominal pain that resembles biliary colic. Fever, cough, and abnormal chest imaging findings assist in differentiation. Hepatitis, whether viral, autoimmune, or drug-induced, may also present with right upper quadrant pain, jaundice, and elevated liver enzymes, closely mimicking gallbladder disease. In these cases, serology and hepatic imaging play important roles in distinguishing between hepatic and biliary pathology [25]. Mesenteric ischemia must also be considered, particularly in older patients presenting with

severe abdominal pain disproportionate to examination findings. The condition carries high morbidity and mortality if missed and requires prompt CT angiography for confirmation. Gastroenteritis, although often accompanied by diarrhea and systemic symptoms, may sometimes present with isolated abdominal pain, nausea, and vomiting, potentially misleading clinicians toward gallstone disease. Overall, the differential diagnosis of gallstone disease encompasses gastrointestinal, hepatobiliary, renal, cardiovascular, pulmonary, and systemic disorders. Because many of these conditions share overlapping features, accurate history-taking, targeted physical examination, and judicious use of laboratory and imaging modalities are essential to reach the correct diagnosis. Thorough consideration of alternative causes ensures timely and appropriate treatment, minimizing the risk of misdiagnosis and preventing complications [25].

Pertinent Studies and Ongoing Trials

Shenoy and colleagues reviewed the literature on adult symptomatic cholelithiasis published between 2000 and 2020. The review compared operative and nonoperative strategies. Outcomes included length of stay and readmission. The review examined cholecystectomy versus observation, cholecystectomy versus lithotripsy, elective versus urgent cholecystectomy, pharmacologic attempts to dissolve stones, and pain management compared with observation. [2] The analysis synthesized clinical trials and observational studies to evaluate effectiveness and resource use. The review found consistent superiority of surgical management for symptom control when compared with lithotripsy. Patients who underwent cholecystectomy achieved more durable pain relief. Lithotripsy provided transient benefit in some cases but carried higher recurrence. For patients with severe uncontrolled pain, operative intervention outperformed observation in preventing recurrent emergency visits and progressive morbidity. The authors reported that patients assigned to observation often required additional acute care before a definitive procedure. [2] When elective and urgent operative timing were compared, the review identified practical harms of delay. About one quarter of patients scheduled for elective cholecystectomy required interim treatment for worsening symptoms prior to the planned operation. This finding underscored that deferred surgery can expose patients to avoidable episodes and higher short term costs. The pooled evidence did not show advantages for delayed intervention in symptomatic cohorts. [2]

Pharmacologic dissolution with chenodeoxycholic acid or ursodeoxycholic acid did not outperform placebo for pain reduction or stone dissolution in the trials reviewed. Studies that tested acupuncture as a means to promote stone clearance or reduce symptoms also failed to demonstrate benefit over observation. Trials of targeted analgesic strategies showed mixed results. Loxiglumide, a cholecystokinin 1 receptor antagonist, produced superior pain control compared with hyoscine N butyl bromide in a randomized comparison. [2] These pharmacologic data suggest limited roles for nonoperative agents and highlight the persistent efficacy gap between medical measures and cholecystectomy. Shenoy et al recommended a strategy that stratifies patients by symptom pattern. Key variables include time from symptom onset and frequency and severity of recurrent attacks. Stratification enables clinicians to estimate risk of complication while awaiting elective surgery. The authors argued that early definitive treatment for appropriately selected symptomatic patients prevents clinical decline experienced during wait intervals and reduces downstream costs and morbidity. They emphasized the need to match treatment intensity with the patient level of risk and symptom burden. [2]

The SECURE trial tested management approaches for uncomplicated symptomatic cholelithiasis and measured eventual operation rates. The trial showed that some conservative strategies modestly reduced the need for surgery in a subset of patients. However, these strategies did not produce clinically meaningful reductions in pain or in the overall requirement for operative intervention. The trial reinforced that nonoperative approaches may defer but rarely obviate the need for cholecystectomy among symptomatic adults. [26] Taken together the evidence supports early surgical management for individuals with persistent or recurrent biliary symptoms. Nonoperative and pharmacologic options remain of limited efficacy for most symptomatic patients. Patient selection based on symptom chronology and severity optimizes outcomes and resource use. Current data also identify gaps for future research. Comparative trials that focus on patient centered outcomes, cost effectiveness, and stratified care pathways would help refine indications for early versus delayed surgery. Studies that explore combinations of medical, endoscopic, and minimally invasive techniques for complex cases may also clarify roles for nonoperative alternatives in defined subgroups.

Prognosis

Gallstone disease is often benign. Most individuals with gallstones remain asymptomatic. Fewer than half of those with stones develop symptoms. Despite this, population studies link cholelithiasis to higher long term mortality from cardiovascular disease and cancer. [27] When intervention is required, outcomes are generally favorable. After elective laparoscopic cholecystectomy patients typically recover well and return to usual activities. Some report mild postprandial gastrointestinal complaints such as bloating or diarrhea, especially after fatty meals. Overall life expectancy and quality of life after cholecystectomy approximate those of people without gallstones. Perioperative mortality after elective laparoscopic cholecystectomy is low. Reported death rates are under 0.5 percent in most series. Mortality rises for emergency operations. A multicenter study from India reported a 30 day morbidity of 11 percent and a 30 day mortality of 0.2 percent. Factors linked to higher morbidity included elevated body mass index, prior abdominal surgery, dense intraabdominal adhesions, conversion to open surgery, and gangrenous gallbladder at operation. In that cohort the conversion rate from laparoscopy to open repair was 1.3 percent and the bile duct injury rate was 0.3 percent. [28] Obesity alone is not reliably predictive of worse surgical outcomes. A large series of 4,699 laparoscopic cholecystectomies identified patients with body mass index above 35 and compared them with leaner controls. The investigators found no significant differences in operative time, complication rates, readmission, or mortality. These data suggest that morbid obesity should not automatically preclude a standard laparoscopic approach when other risk factors are controlled. [29]

Frailty and acute disease severity do affect outcomes. Studies using the Modified Frailty Index show that greater frailty correlates with higher postoperative morbidity and mortality after laparoscopic cholecystectomy for acute cholecystitis. Frailty assessment can inform preoperative risk stratification and perioperative planning. [30] A recent multicenter

observational effort led to a validated preoperative risk score for patients undergoing cholecystectomy for acute calculous cholecystitis. In that study of 1,253 patients across 79 centers the 30 day morbidity was 6.6 percent and the 30 day mortality was 1 percent. The score helps identify patients at elevated risk and guides decisions about timing and level of care. [31] Prognosis depends on patient factors and on disease context. Asymptomatic stones carry a low short term risk. Symptomatic disease that is treated electively has low mortality and acceptable morbidity. Emergency presentations, severe inflammation, sepsis, or coexisting frailty raise the risk of adverse outcomes. Preoperative risk assessment and targeted perioperative management reduce complications. When clinical teams tailor care to patient risk the net benefit of operative management for symptomatic gallstones remains high.

Complications

Gallstones provoke a spectrum of adverse events that range from localized inflammation to life-threatening systemic illness. Obstruction of gallbladder outflow by impacted calculi commonly initiates an inflammatory cascade that progresses from uncomplicated acute cholecystitis to complicated forms such as empyema, gangrenous cholecystitis, and emphysematous cholecystitis. These entities reflect escalating tissue ischemia, bacterial invasion, and necrosis within the gallbladder wall. Empyema denotes purulent accumulation within the lumen and often coincides with systemic sepsis. Gangrene indicates transmural necrosis that raises the risk of perforation and peritonitis. Emphysematous cholecystitis, frequently associated with gas-forming organisms and comorbid diabetes, carries an especially high morbidity and may necessitate urgent source control. [32][33][34] Calculi that migrate into or lodge near the common bile duct produce obstructive sequelae with significant downstream consequences. Obstruction produces cholestasis with progressive proximal dilation of the biliary tree, biochemical cholestatic liver injury, and clinically evident jaundice. When biliary outflow is interrupted at or near the ampulla of Vater, reflux of bile and bacterial translocation predispose to ascending cholangitis, an infection that can rapidly progress to sepsis without prompt decompression and antimicrobial therapy. Impaction at the ampullary region may also precipitate acute gallstone pancreatitis by obstructing pancreatic enzyme drainage, with potential for severe systemic inflammatory response and multiorgan dysfunction. [32][33][34]

External compression of the biliary ducts by an impacted cystic duct stone or an inflamed gallbladder neck can produce a distinct clinical entity known as Mirizzi syndrome. In Mirizzi syndrome the mechanical obstruction and local inflammatory reaction may progressively erode ductal tissue and lead to biliary stricturing and secondary cholestasis. Persistent impaction and chronic inflammation may ultimately result in fistulization. A chronically impacted stone can erode through the gallbladder wall into adjacent hollow viscera, most commonly producing a cholecystoenteric fistula with the duodenum; when a large gallstone passes into the intestinal lumen and becomes lodged in the distal small bowel, a mechanical obstruction termed gallstone ileus ensues. Although rare, gallstone ileus produces significant obstructive symptoms and accounts for 0.3% to 0.5% of patients with gallstones who develop bowel obstruction. Bouveret syndrome describes the related but more proximal gastric outlet obstruction that follows stone impaction at the duodenum. These complex presentations often demand combined surgical and endoscopic management. [9][10][35]

Procedural and therapeutic interventions directed at biliary pathology introduce procedure-specific risks. Endoscopic retrograde cholangiopancreatography (ERCP), while indispensable for both diagnosis and removal of ductal stones, carries complications including post-ERCP pancreatitis, hemorrhage (haemobilia), iatrogenic injury to the bile ducts or duodenum, and, rarely, pulmonary bile embolism reported after ERCP for gallstone pancreatitis. The frequency and severity of these events depend on patient factors and operator experience. During cholecystectomy, whether laparoscopic or open, surgery-related complications include inadvertent bile duct or bowel injury, retained common bile duct stones, postoperative bile leak, incisional hernia, and the persistence of chronic right upper quadrant pain. Bile duct injury, though uncommon in experienced hands, represents a devastating complication that may require complex reconstructive surgery and carries long-term morbidity. [10][36] Postoperative recovery spans a broad clinical spectrum determined by the preoperative condition and perioperative course. Uncomplicated elective cholecystectomy frequently results in same-day discharge and rapid convalescence, whereas patients with ascending cholangitis, severe gallstone pancreatitis, or septic complications may require prolonged critical care, multiorgan support, and staged interventions. Dietary counseling for low-fat, small-portion meals is commonly advised following discharge to reduce symptomatic intolerance; many patients experience transient post-cholecystectomy changes in bowel habits that typically improve over time.

Patient Education:

Prevention and patient education mitigate some risks associated with stone disease. Diets higher in monounsaturated fats, fiber, olive oil, omega-3 fatty acids, and vegetable protein appear protective. Polyunsaturated fatty acids and specific dietary patterns may promote gallbladder emptying, while vitamin C–rich produce and coffee consumption have been linked to improved motility. Regular physical activity reduces risk, whereas diets high in refined sugars, fructose, and saturated fats, combined with low fiber intake and insulin-resistant metabolic states, increase lithogenic potential. Clinicians advising patients who choose conservative management for biliary colic must emphasize red flags—persistent or worsening pain, fever, jaundice, or systemic symptoms—and instruct prompt presentation for evaluation because delay increases the chance of stone impaction, infection, and emergency intervention. [8][12][37] Clinical decision making recognizes that asymptomatic choledocholithiasis and asymptomatic cholelithiasis can sometimes be observed without immediate intervention, provided the patient is informed and able to access care if symptoms develop. However, asymptomatic status does not remove the risk of severe complications such as cholangitis, pancreatitis, or fistula formation, and clinicians must counsel patients accordingly. Impacted stones may precipitate gangrenous cholecystitis or progressive erosion producing cholecystoenteric or choledochoduodenal fistulae; these outcomes demand complex operative management and increase perioperative risk. [38][39][40][41] Pregnancy presents distinct considerations. Gallstones during pregnancy are associated with higher maternal and neonatal morbidity, including an increased risk of preterm birth. When symptomatic disease requires intervention,

cholecystectomy can be performed safely during the second trimester and, in selected centers, during the early or mid-stages of pregnancy, balancing maternal benefit and fetal risk. [11]

Outcomes:

Optimal outcomes derive from early multidisciplinary involvement. An interprofessional model combining primary care, radiology, gastroenterology, general surgery, interventional radiology, anesthesiology, nursing, and nutrition services improves the timing of elective interventions, reduces emergency presentations, and enhances perioperative planning. Early surgical consultation for recurrent symptoms facilitates elective rather than emergent management and lowers complication rates. Not all patients require cholecystectomy; lifestyle modification and medical management are appropriate in selected cases, but when operative therapy is indicated, coordinated preoperative optimization and postoperative education reduce morbidity and improve recovery. Close communication among team members remains central to minimizing the morbidity of gallstone disease and ensuring rapid recognition and treatment of its complications. [42][43][44]

Conclusion:

Gallstone disease encompasses a broad clinical spectrum, from an incidental, asymptomatic finding to a source of severe morbidity. Its pathophysiology is multifactorial, involving metabolic imbalances, genetic predisposition, and gallbladder dysmotility. The prognosis for most individuals is excellent, particularly for those with asymptomatic stones or those who undergo elective laparoscopic cholecystectomy for symptomatic disease. This procedure is highly effective, with low mortality and morbidity, and remains the gold standard for definitive management. However, the presentation of complications such as acute cholecystitis, cholangitis, or pancreatitis significantly alters the clinical course, necessitating urgent intervention and carrying higher risks. Therefore, timely diagnosis through ultrasonography and appropriate laboratory testing is critical. Management must be tailored to the individual, balancing the risks of intervention against the natural history of the disease. A multidisciplinary approach involving surgeons, gastroenterologists, and radiologists is paramount for optimizing outcomes, especially in complex cases involving common bile duct stones or critically ill patients. Ultimately, understanding the disease's mechanisms, epidemiology, and evidence-based treatment pathways allows healthcare professionals to provide effective care, alleviate symptoms, and prevent serious complications.

References:

1. Tsai TJ, Chan HH, Lai KH, Shih CA, Kao SS, Sun WC, Wang EM, Tsai WL, Lin KH, Yu HC, Chen WC, Wang HM, Tsay FW, Lin HS, Cheng JS, Hsu PI. Gallbladder function predicts subsequent biliary complications in patients with common bile duct stones after endoscopic treatment? BMC Gastroenterol. 2018 Feb 27;18(1):32.
2. Shenoy R, Kirkland P, Hadaya JE, Tranfield MW, DeVirgilio M, Russell MM, Maggard-Gibbons M. Management of symptomatic cholelithiasis: a systematic review. Syst Rev. 2022 Dec 12;11(1):267.
3. Di Ciaula A, Garruti G, Frühbeck G, De Angelis M, de Bari O, Wang DQ, Lammert F, Portincasa P. The Role of Diet in the Pathogenesis of Cholesterol Gallstones. Curr Med Chem. 2019;26(19):3620-3638.
4. Rebholz C, Krawczyk M, Lammert F. Genetics of gallstone disease. Eur J Clin Invest. 2018 Jul;48(7):e12935.
5. E S, Srikanth MS, Shreyas A, Desai S, Mehdi S, Gangadharappa HV, Suman, Krishna KL. Recent advances, novel targets and treatments for cholelithiasis; a narrative review. Eur J Pharmacol. 2021 Oct 05;908:174376.
6. Hapca S, Ramsay G, Murchie P, Ahmed I. Biliary colic. BMJ. 2021 Sep 13;374:n2085.
7. Unalp-Arida A, Ruhl CE. Burden of gallstone disease in the United States population: Prepandemic rates and trends. World J Gastrointest Surg. 2024 Apr 27;16(4):1130-1148.
8. Gutt C, Schläfer S, Lammert F. The Treatment of Gallstone Disease. Dtsch Arztebl Int. 2020 Feb 28;117(9):148-158.
9. Fujita N, Yasuda I, Endo I, Isayama H, Iwashita T, Ueki T, Uemura K, Umezawa A, Katanuma A, Katayose Y, Suzuki Y, Shoda J, Tsuyuguchi T, Wakai T, Inui K, Unno M, Takeyama Y, Itoi T, Koike K, Mochida S. Evidence-based clinical practice guidelines for cholelithiasis 2021. J Gastroenterol. 2023 Sep;58(9):801-833.
10. Cianci P, Restini E. Management of cholelithiasis with choledocholithiasis: Endoscopic and surgical approaches. World J Gastroenterol. 2021 Jul 28;27(28):4536-4554.
11. Di Ciaula A, Wang DQ, Portincasa P. An update on the pathogenesis of cholesterol gallstone disease. Curr Opin Gastroenterol. 2018 Mar;34(2):71-80.
12. Kotrotsios A, Tasis N, Angelis S, Apostolopoulos AP, Vlasis K, Papadopoulos V, Filippou DK. Dietary Intake and Cholelithiasis: A Review. J Long Term Eff Med Implants. 2019;29(4):317-326.
13. Shabanzadeh DM. New determinants for gallstone disease?. Dan Med J. 2018 Feb;65(2)
14. Sun H, Warren J, Yip J, Ji Y, Hao S, Han W, Ding Y. Factors Influencing Gallstone Formation: A Review of the Literature. Biomolecules. 2022 Apr 06;12(4)
15. Haal S, Guman MSS, Acherman YIZ, Jansen JPG, van Weeghel M, van Lenthe H, Wever EJM, Gerdes VEA, Voermans RP, Groen AK. Gallstone Formation Follows a Different Trajectory in Bariatric Patients Compared to Nonbariatric Patients. Metabolites. 2021 Oct 05;11(10)
16. Boyang H, Yanjun Y, Jing Z, Chenxin Y, Ying M, Shuwen H, Qiang Y. Investigating the influence of the gut microbiome on cholelithiasis: unveiling insights through sequencing and predictive modeling. J Appl Microbiol. 2024 May 01;135(5)
17. Hu H, Shao W, Liu Q, Liu N, Wang Q, Xu J, Zhang X, Weng Z, Lu Q, Jiao L, Chen C, Sun H, Jiang Z, Zhang X, Gu A. Gut microbiota promotes cholesterol gallstone formation by modulating bile acid composition and biliary cholesterol secretion. Nat Commun. 2022 Jan 11;13(1):252.
18. Sharma R, Sachan SG, Sharma SR. In vitro analysis of gallstone formation in the presence of bacteria. Indian J Gastroenterol. 2020 Oct;39(5):473-480.

19. Shi T, Li D, Li D, Sun J, Xie P, Wang T, Li R, Li Z, Zou Z, Ren X. Individual and joint associations of per- and polyfluoroalkyl substances (PFAS) with gallstone disease in adults: A cross-sectional study. Chemosphere. 2024 Jun;358:142168.
20. Luo M, Chen P, Tian Y, Rigzin N, Sonam J, Shang F, Tai C, Li T, Sang H. Hif-1α expression targets the TMA/Fmo3/TMAO axis to participate in gallbladder cholesterol stone formation in individuals living in plateau regions. Biochim Biophys Acta Mol Basis Dis. 2024 Jun;1870(5):167188.
21. Wilkins T, Agabin E, Varghese J, Talukder A. Gallbladder Dysfunction: Cholecystitis, Choledocholithiasis, Cholangitis, and Biliary Dyskinesia. Prim Care. 2017 Dec;44(4):575-597.
22. Hiwatashi K, Okumura H, Setoyama T, Ando K, Ogura Y, Aridome K, Maenohara S, Natsugoe S. Evaluation of laparoscopic cholecystectomy using indocyanine green cholangiography including cholecystitis: A retrospective study. Medicine (Baltimore). 2018 Jul;97(30):e11654.
23. Gallaher JR, Charles A. Acute Cholecystitis: A Review. JAMA. 2022 Mar 08;327(10):965-975.
24. Han JH, So H, Bang SJ, Nah YW. [Surgical Removal of a Huge Common Bile Duct Stone]. Korean J Gastroenterol. 2024 May 25;83(5):200-204.
25. Hirajima S, Koh T, Sakai T, Imamura T, Kato S, Nishimura Y, Soga K, Nishio M, Oguro A, Nakagawa N. Utility of Laparoscopic Subtotal Cholecystectomy with or without Cystic Duct Ligation for Severe Cholecystitis. Am Surg. 2017 Nov 01;83(11):1209-1213.
26. Comes DJ, Wennmacker SZ, Latenstein CSS, van der Bilt J, Buyne O, Donkervoort SC, Heisterkamp J, In't Hof K, Jansen J, Nieuwenhuijs VB, Steenvoorde P, Stockmann HBAC, Boerma D, Drenth JPH, van Laarhoven CJHM, Boermeester MA, Dijkgraaf MGW, de Reuver PR. Restrictive Strategy vs Usual Care for Cholecystectomy in Patients With Abdominal Pain and Gallstones: 5-Year Follow-Up of the SECURE Randomized Clinical Trial. JAMA Surg. 2024 Nov 01;159(11):1235-1243.
27. Ruhl CE, Everhart JE. Gallstone disease is associated with increased mortality in the United States. Gastroenterology. 2011 Feb;140(2):508-16.
28. Thapar VB, Thapar PM, Goel R, Agarwalla R, Salvi PH, Nasta AM, Mahawar K., IAGES Research Collaborative Group. Evaluation of 30-day morbidity and mortality of laparoscopic cholecystectomy: a multicenter prospective observational Indian Association of Gastrointestinal Endoscopic Surgeons (IAGES) Study. Surg Endosc. 2023 Apr;37(4):2611-2625.
29. Nassar AHM, Khan KS, Ng HJ, Sallam M. Operative Difficulty, Morbidity and Mortality Are Unrelated to Obesity in Elective or Emergency Laparoscopic Cholecystectomy and Bile Duct Exploration. J Gastrointest Surg. 2022 Sep;26(9):1863-1872.
30. Fagenson AM, Powers BD, Zorbas KA, Karhadkar S, Karachristos A, Di Carlo A, Lau KN. Frailty Predicts Morbidity and Mortality After Laparoscopic Cholecystectomy for Acute Cholecystitis: An ACS-NSQIP Cohort Analysis. J Gastrointest Surg. 2021 Apr;25(4):932-940.
31. Fugazzola P, Cobianchi L, Di Martino M, Tomasoni M, Dal Mas F, Abu-Zidan FM, Agnoletti V, Ceresoli M, Coccolini F, Di Saverio S, Dominioni T, Farè CN, Frassini S, Gambini G, Leppäniemi A, Maestri M, Martín-Pérez E, Moore EE, Musella V, Peitzman AB, de la Hoz Rodríguez Á, Sargenti B, Sartelli M, Viganò J, Anderloni A, Biffl W, Catena F, Ansaloni L., S.P.Ri.M.A.C.C. Collaborative Group. Prediction of morbidity and mortality after early cholecystectomy for acute calculous cholecystitis: results of the S.P.Ri.M.A.C.C. study. World J Emerg Surg. 2023 Mar 18;18(1):20.
32. Del Vecchio Blanco G, Gesuale C, Varanese M, Monteleone G, Paoluzi OA. Idiopathic acute pancreatitis: a review on etiology and diagnostic work-up. Clin J Gastroenterol. 2019 Dec;12(6):511-524.
33. Brägelmann J, Barahona Ponce C, Marcelain K, Roessler S, Goeppert B, Gallegos I, Colombo A, Sanhueza V, Morales E, Rivera MT, de Toro G, Ortega A, Müller B, Gabler F, Scherer D, Waldenberger M, Reischl E, Boekstegers F, Garate-Calderon V, Umu SU, Rounge TB, Popanda O, Lorenzo Bermejo J. Epigenome-Wide Analysis of Methylation Changes in the Sequence of Gallstone Disease, Dysplasia, and Gallbladder Cancer. Hepatology. 2021 Jun;73(6):2293-2310
34. Sohail Z, Shaikh H, Iqbal N, Parkash O. Acute pancreatitis: A narrative review. J Pak Med Assoc. 2024 May;74(5):953-958.
35. Zaher EA, Ebrahim MA, Al Salman O, Patel P, Alchalabi M. Bigger Than a Hen's Egg: A Case of Bouveret Syndrome. Cureus. 2024 Apr;16(4):e58742.
36. Knapik M, Okoń K, Ulatowska-Białas M. Fatal pulmonary bile embolism associated with acute pancreatitis - a case report and review of the literature. Pol J Pathol. 2024;75(1):54-57.
37. Gross AR, Bacaj PJ, Williams HJ. Educational Case: Gallstones, Cholelithiasis, and Cholecystitis. Acad Pathol. 2020 Jan-Dec;7:2374289520951902.
38. Field X, Tong C, Cox S, Crichton J, Goodwin B, Welsh F, Cha R. Outcomes of asymptomatic common bile duct stones detected at intraoperative cholangiography. N Z Med J. 2024 May 17;137(1595):73-79.
39. Katta T, Tavakoli K. Necrotizing Cholecystitis in the Gallbladder: A Case Report. Cureus. 2022 Jan;14(1):e21368.
40. Park JM, Kang CD, Kim JH, Lee SH, Nam SJ, Park SC, Lee SJ, Lee S. Cholecystoduodenal fistula presenting with upper gastrointestinal bleeding: A case report. World J Clin Cases. 2021 Jan 16;9(2):410-415.
41. B S B, Kar A, Dutta M, Mandal A, De Bakshi S. A case of choledochoduodenal fistula - an unusual case report. Clin Case Rep. 2017 Sep;5(9):1462-1464.
42. Patel SS, Kohli DR, Savas J, Mutha PR, Zfass A, Shah TU. Surgery Reduces Risk of Complications Even in High-Risk Veterans After Endoscopic Therapy for Biliary Stone Disease. Dig Dis Sci. 2018 Mar;63(3):781-786.
43. Genser L, Vons C. Can abdominal surgical emergencies be treated in an ambulatory setting? J Visc Surg. 2015 Dec;152(6 Suppl):S81-9.
44. Coleman J. Bile duct injuries in laparoscopic cholecystectomy: nursing perspective. AACN Clin Issues. 1999 Nov;10(4):442-54.